MC Press Lounge: MC Services supports companies and media at BIO-Europe 2016

This fall, Cologne is hosting Europe’s largest partnering conference for the global biotechnology industry - BIO-Europe®. The event will take place November 7-9 and is expected to draw over 3,500 attendees from over 50 countries. MC Services is supporting BIO-Europe® as media partner and cordially invites you to this event.

Take advantage of the new conference Press Lounge. Centrally located in the exhibit hall – in the midst of activities – you can retreat to a quiet, fully-equipped work station or use the lounge area to conduct interviews or network with industry representatives. Please feel free to contact us! We look forward to welcoming you and are happy to help you arrange interviews.

Accredited journalists are invited to register online or at the press desk at the main entrance and will be able to attend the conference free of charge. Detailed information on accreditation and registration can be found here. Please enter "MC Services Guest" in the comment field when registering online.

Please find the complete program here.

We would also like to draw your attention to the following event:

Press Conference / Mini-Symposium
“Challenges and breakthroughs of anti-infective therapies –
10 years of AiCuris!”

Tuesday, November 8, 11:00am – 12:00 noon – BIO.NRW booth no. 100

as part of AiCuris Anti-infective Cures GmbH’s 10th anniversary celebration.



Prof. Dr. Theodor Dingermann, Goethe University Frankfurt, Institute for Pharmaceutical Biology, Moderator

Prof. Dr. med. Andrew Ullmann, University Hospital Würzburg, Infectious Diseases
“Current challenges in anti-infective therapies: a clinician’s perspective“

Dr. Holger Zimmermann, CEO, AiCuris Anti-infective Cures GmbH, Wuppertal, Germany
“AiCuris: 10 years of successful R&D in anti-infective therapies“

For your background discussions:
Many of our clients will be available for background interviews or as experts on current trends in the biotech industry. We will be glad to provide you more information about any of these companies and the sectors in which they operate.

Abivax SA (#HIV; #AntiInfectives): Prof. Dr. Hartmut Ehrlich, CEO (German/English)

Adocia SA (#Diabetes; #BioChaperone): Dr. Rémi Soula, Co-founder, Director Business Development and Intellectual Property (English/French)

AiCuris Anti-Infective Cures GmbH (#AntiInfectives): Dr. Holger Zimmermann, CEO (German/English)

Apogenix AG (#ImmunoOncology, drug candidates that target different TNFSF-dependent signaling pathways): Dr. Thomas Höger, CEO (German/English)

CEVEC GmbH (#Glycoprotein; #GeneTherapy; #ViralVectors): Frank Ubags, CEO (German/English)

Cinfa Biotech SA (#Biosimilars, #PegfilgrastimBiosimilar): Dr. Rüdiger Jankowsky, Managing Director (German/English)

Creathor Venture Management GmbH (#VentureCapital): Karlheinz Schmelig, Managing Partner; Dr. Aristotelis Nastos, Partner (German/English)

Ergomed plc (#CRO; #Co-Development; #OrphanDiseases): Andrew Mackie, CBO (English)

InflaRx GmbH (#ComplementC5a,#Antibody, #Inflammation):Dr. Niels Riedemann, CEO, Arnd Christ, CFO(German/English)

Neovacs SA (#Kinoid, #AutoimmuneDiseases, #Cancer): Miguel Sieler, CEO (English/French/German)

Nicox SA (#Ophthalmology; #NO-Donors): Dr. Michele Garufi, CEO (English/French/Italian)

ORYX GmbH & Co. KG (#OncolyticVirus; #TherapeuticVaccines): Dr. Bernhard Huber, CEO (German/English)

PAION AG (#Sedation, #Anaesthesia; Positive Phase III data with Remimazolam): Dr. Wolfgang Söhngen, CEO (German/English)

Probiodrug AG (#AlzheimersDisease): Dr. Konrad Glund, CEO (German/English)

Redhill Biopharma Ltd. (#Microbiome; #Helicobacterpylori; #CrohnsDisease; #MultipleSclerosis; #Gastroenterology; #Oncology): Adi Frish, Senior VP Business Development and Licensing (English)

Rentschler Biotechnologie GmbH (#CDMO, #BiologicsManufacturing, #GrowthStrategy): Dr. Frank Mathias, CEO (German/English/French)

Sygnis AG (#NextGenerationSequencing, #M&A, merger with Expedeon): Pilar de la Huerta, Co-CEO & CFO (English/Spanish)

Transgene SA (#TargetedImmunotherapy, #OncolyticViruses, #InfectiousDiseases, #Cancer): Dr. Philippe Archinard, CEO (English/French)

VAXIMM AG (oral #T-cellImmunotherapies, #CancerVaccine): Dr. Matthias Schroff, CEO; Dr. Heinz Lubenau, COO (German/English)

WILEX AG (#Oncology; #AntibodyDrugConjugatesPlatform; #BCMA-ADC; #Amanitin): Dr. Jan Schmidt-Brand, CEO (German/English)

Xenikos B.V. (#GVHD; #ImmuneModulator; #Transplantation, #OrphanDiseases): Ypke van Oosterhout, CEO (English)

We look forward to welcoming you in the Press Lounge and would be glad to arrange background discussions and interviews with company and industry representatives. We are happy to be at your disposal for any questions and/or further information.


MC SERVICES AG, www.mc-services.eu; Twitter: @MCServicesAG
Caroline Bergmann, Phone: +49 211 529252 20, Mail: caroline.bergmann@mc-services.eu

Seite drucken Top